指南与共识湿疹皮炎与荨麻疹

全球皮肤病学指南映射项目(GUIDEMAP):关于特应性皮炎临床实践指南的系统综述——它们是否清晰、无偏倚、可信且基于证据(CUTE)?

Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
指南 / 共识 · Br J Dermatol · 2022-01-01

该研究系统检索了2016年4月1日至2021年4月1日发表的40部特应性皮炎临床实践指南,采用AGREE II报告清单、美国医学研究所(IOM)可信性标准和Lenzer红旗标志评估其清晰性、无偏倚性、可信性和证据基础。结果显示指南报告质量差异巨大,仅3部在所有AGREE II领域评为优秀,1部完全满足全部9条IOM标准,3部无红旗标志,适用性和制定的严谨性得分最低,利益冲突管理具有挑战性。

要点

  • 共纳入40部特应性皮炎指南,多来自高社会人口指数国家,报告质量差异极大。
  • 仅3部指南在所有AGREE II领域评分为优秀,3部在所有领域评分为差。
  • 仅1部完全满足全部9条IOM可信性标准,3部无Lenzer红旗标志。

核心结论

  • 总体而言,许多指南不够清晰、无偏倚、可信或基于证据,且缺乏适用性,因此有必要改进,推荐使用AGREE II工具。
  • 一些改进可通过稳健的报告轻松实现,而透明度、适用性、证据基础和利益冲突管理可能需要更多努力。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase、PubMed、Web of Science、Cochrane Library、Emcare、Epistemonikos、PsycINFO和Academic Search Premier,纳入2016年4月1日至2021年4月1日发表的关于特应性皮炎的临床实践指南,并手工检索预设指南资源。
  • 由两名作者独立进行筛选、数据提取和质量评估,使用AGREE II报告清单、美国医学研究所(IOM)可信性标准和Lenzer红旗标志进行评估。

主要发现

  • 共纳入40部指南,大多来自高社会人口指数国家;报告质量差异巨大:3部指南在所有AGREE II领域评分为优秀,3部在所有领域评分为差。
  • 未发现AGREE II评分与国家国内生产总值之间存在关联。
  • 1部指南完全满足全部9条IOM标准,2部完全满足8条;3部指南无红旗标志。
  • AGREE II评分最低的领域为适用性和制定的严谨性;IOM标准满足最少的为外部评审、更新程序和推荐强度分级;大多数红旗标志涉及方法学专家参与有限或缺失以及无外部评审。
  • 利益冲突管理似乎具有挑战性;当各工具 constructs 重叠时,显示出高度一致性,强化了结论。

关键数值与推荐

  • AGREE II评分最低领域:适用性和制定的严谨性。
  • IOM标准满足最少:外部评审、更新程序和推荐强度分级。
  • 最常见红旗标志:方法学专家参与有限或缺失、无外部评审。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical practice guidelines (CPGs) are essential in delivering optimum healthcare, such as for atopic dermatitis (AD), a highly prevalent skin disease. Although many CPGs are available for AD, their quality has not been critically appraised. OBJECTIVES: To identify CPGs on AD worldwide and to assess with validated instruments whether those CPGs are clear, unbiased, trustworthy and evidence based (CUTE). METHODS: We searched MEDLINE, Embase, PubMed, Web of Science, Cochrane Library, Emcare, Epistemonikos, PsycINFO and Academic Search Premier for CPGs on AD published between 1 April 2016 and 1 April 2021. Additionally we hand searched prespecified guideline resources. Screening, data extraction and quality assessment of eligible guidelines were independently carried out by two authors. Instruments used for quality assessment were the AGREE II Reporting Checklist, the US Institute of Medicine (IOM) criteria of trustworthiness and Lenzer's Red Flags. RESULTS: Forty CPGs were included, mostly from countries with a high sociodemographic index. The reporting quality varied enormously. Three CPGs scored 'excellent' on all AGREE II domains and three scored 'poor' on all domains. We found no association between AGREE II scores and a country's gross domestic product. One CPG fully met all nine IOM criteria and two fully met eight. Three CPGs had no red flags. 'Applicability' and 'rigour of development' were the lowest scoring AGREE II domains; 'external review', 'updating procedures' and 'rating strength of recommendations' were the IOM criteria least met; and most red flags were for 'limited or no involvement of methodological expertise' and 'no external review'. Management of conflicts of interest (COIs) appeared challenging. When constructs of the instruments overlapped, they showed high concordance, strengthening our conclusions. CONCLUSIONS: Overall, many CPGs are not sufficiently clear, unbiased, trustworthy or evidence based (CUTE) and lack applicability. Therefore improvement is warranted, for which using the AGREE II instrument is recommended. Some improvements can be easily accomplished through robust reporting. Others, such as transparency, applicability, evidence foundation and managing COIs, might require more effort.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Arents BWM, van Zuuren EJ, Vermeulen S, et al. Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)? Br J Dermatol. 2022. PMID: 34984668. doi:10.1111/bjd.20972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。